Study of YK012 for membranous nephropathy
Treatments studied
Part of Kidney & urinary clinical trials.
This trial tests an investigational drug called YK012 for people with a kidney disease called primary membranous nephropathy. The study aims to see if YK012 is safe and helpful for those whose condition is very high risk and has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with primary membranous nephropathy by a kidney biopsy within the last 10 years.
- Your kidney function is at least 45 mL/min/1.73 m².
- You have already tried standard treatments and they did not work well enough.
- You do not have certain other medical conditions (like recent cancer, uncontrolled infections, or a history of kidney transplant).
- You are willing to use effective contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
This trial tests a new drug called B007 for people with primary membranous nephropathy, a kidney condition. It aims to see if B007 can help reduce protein in the urine and protect kidney function.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
This study tests a new gel that contains a natural hormone to quiet the immune attack on kidneys. It is for people whose membranous nephropathy is at high risk of getting worse.
This trial tests a new treatment called FKC289 for people whose membranous nephropathy (a kidney condition where the immune system attacks the kidney's filters) has come back or not improved with other treatments. The goal is to see if FKC289 is safe and can reduce protein in the urine, which indicates how well the kidney is working.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.